CDEK
← All drugs Report issue

dalpiciclib

Small moleculeexperimental

Clinical trial activity

99 trials · 32 clinical orgs · 0 marketing orgs

Phase 1
32
Phase 2
74
Phase 3
6
Phase 4
1

Earliest trial started Jan 1, 2016 (NCT02671513)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)c1c(C)c2cnc(Nc3ccc(C4CCNCC4)cn3)nc2n(C2CCCC2)c1=O
Mol. weight
446.56 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • shr6390

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07207070Phase 3Nov 28, 2025Innovaderm, Risen (Suzhou) Pharma Tech Co., Ltd.
NCT07238881Phase 2Nov 5, 2025Sun Yat-Sen University
NCT07101159Phase 2Sep 30, 2025Fujian Medical University
NCT07189884Phase 1/Phase 2 (Phase 2)Sep 23, 2025Xiamen University
NCT07179939Phase 2Sep 10, 2025Fudan University, Hengrui Therapeutics, Inc., People's Liberation Army of China
NCT07117630Phase 2Aug 31, 2025Fudan University
NCT07285382Phase 2Jun 25, 2025Qingdao University
NCT07037199Phase 2Jun 20, 2025Sun Yat-Sen University
NCT06970912Phase 2Jun 1, 2025Peking University
NCT06935188Phase 2Apr 17, 2025Jiao Tong University
NCT06810492N/AApr 1, 2025Wuhan University
NCT06711094N/AJan 1, 2025Fujian Medical University
NCT06650748Phase 2Nov 15, 2024Peking University
NCT06684600Phase 2Nov 1, 2024Peking University
NCT06605690N/AOct 31, 2024Guizhou Medical University
NCT06613373Phase 4Oct 15, 2024Guangzhou Pharmaceucal Company Limited
NCT06556862Phase 2Oct 1, 2024People's Liberation Army of China
NCT06599216Phase 2Sep 15, 2024Harbin Medical University
NCT06612814Phase 3Sep 1, 2024China Medical University, Chongqing Medical University, Dalian Medical University, Fudan University, Fujian Medical University, Jiao Tong University, Nanjing Medical University, Nantong University, Ningbo Medical Center Lihuili Eastern Hospital, Peking University, Sun Yat-Sen University
NCT06552858Phase 2Sep 1, 2024Fudan University
Showing 20 of 99 trials
Page 1 / 5

Organizations

Research & Development (32)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hengrui Therapeutics, Inc.For profit351842016
Fudan UniversityAcademic/Hospital171722018
Sun Yat-Sen UniversityAcademic/Hospital10722019
Peking UniversityAcademic/Hospital9532016
Jiao Tong UniversityAcademic/Hospital7422020
Chinese Academy of Medical SciencesAcademic/Hospital6322016
Fujian Medical UniversityAcademic/Hospital6332022
Tianjin Medical UniversityAcademic/Hospital6612021
Sichuan UniversityAcademic/Hospital5522023
Henan Medical UniversityAcademic/Hospital4412020
Nanjing Medical UniversityAcademic/Hospital4122023
China Medical UniversityAcademic/Hospital3022023
Chongqing Medical UniversityAcademic/Hospital3022023
Dalian Medical UniversityAcademic/Hospital3022023
Nantong UniversityAcademic/Hospital3022023
Ningbo Medical Center Lihuili Eastern HospitalAcademic/Hospital3022023
People's Liberation Army of ChinaGovernment3222022
Qingdao UniversityAcademic/Hospital3322019
Shengjing HospitalAcademic/Hospital3322020
Harbin Medical UniversityAcademic/Hospital2212018
32 organizations
Page 1 / 2